FDA ex­pert pan­el unan­i­mous­ly rec­om­mends ap­proval for Hori­zon Ther­a­peu­tics eye drug

An FDA ad­vi­so­ry com­mit­tee not­ed with con­cern a small safe­ty data­base but unan­i­mous­ly en­dorsed a Hori­zon Ther­a­peu­tics drug for a rare eye au­toim­mune dis­ease that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER